A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms

NCT02298192 · Completed

Last updated 2026-05-28

This clinical trial compares two different methods of adjusting doses of a diabetes medication (IDegLira) in adults with type 2 diabetes to see which method works better.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 420 people

Who can join Ages 18+ · all sexes

Timeline Started 2014-11 · est. completion 2015-12

Where 84 sites · Austria, Bulgaria, Canada, Czechia, Hungary, Russia, Serbia, Slovakia, United States

What this study is testing ClinicalTrials.gov NCT02298192 ↗

Description as written by the study sponsor.

This trial is conducted in Europe, North America and the United States of America. The aim of this trial is to compare two different titration algorithms of insulin degludec/liraglutide.

Treatments tested

insulin degludec/liraglutide Drug

For subcutaneous (s.c., under the skin) injection, once daily. Subjects will be instructed to continue with the same dose of OADs (metformin alone or in combination with pioglitazone), as prior to the trial.

Main thing measured	Change From Baseline in HbA1c
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02298192 ↗